tranexamic acid has been researched along with Inflammation in 38 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Multiple doses of dexamethasone and tranexamic acid can inhibit postoperative inflammation and reduce fibrinolysis and perioperative blood loss in total knee arthroplasty." | 9.69 | Tourniquets can further reduce perioperative blood loss in patients on dexamethasone and tranexamic acid during cemented total knee arthritis: a single-center, double-blind, randomized controlled trial. ( Huang, Q; Jiang, W; Liu, M; Pei, F; Wang, X; Xie, J; Xu, H; Zhou, R; Zhou, Z, 2023) |
| " The purpose of this study was to compare the effects of intra-articular (IA) administration of tranexamic acid (TXA), an anti-fibrinolytic commonly used in TKA, and ALM chondroprotective solution on postoperative inflammation and joint tissue healing in a rat model of knee implant surgery." | 8.02 | Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty. ( Biros, E; Dlaska, C; Dobson, GP; Hazratwala, K; Letson, HL; McEwen, P; Morris, JL; Wilkinson, M, 2021) |
| "Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties." | 7.83 | Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016) |
| " Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology." | 7.74 | Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ( Melchor, JP; Paul, J; Strickland, S, 2007) |
| "The hemostatic effect of tranexamic acid (TXA) combined with carbazochrome sodium sulfonate (CSS) in total hip arthroplasty (THA) has not been determined." | 7.11 | Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial. ( Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022) |
| " Considering the dosage and duration of treatment, an optimal protocol may be needed to induce the efficacy of this treatment to achieve the PIH-preventing effect of oral TA." | 6.76 | A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser. ( Araki, J; Doi, K; Eto, H; Higashino, T; Hirai, R; Kato, H; Kuno, S; Yoshimura, K, 2011) |
| "Tranexamic acid is a promising future treatment for psoriasis." | 5.91 | Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies. ( Chan, CI; Chen, SJ; Hseu, JH; Hseu, YC; Vadivalagan, C; Wu, PY; Yang, HL; Yen, HR, 2023) |
| "Multiple doses of dexamethasone and tranexamic acid can inhibit postoperative inflammation and reduce fibrinolysis and perioperative blood loss in total knee arthroplasty." | 5.69 | Tourniquets can further reduce perioperative blood loss in patients on dexamethasone and tranexamic acid during cemented total knee arthritis: a single-center, double-blind, randomized controlled trial. ( Huang, Q; Jiang, W; Liu, M; Pei, F; Wang, X; Xie, J; Xu, H; Zhou, R; Zhou, Z, 2023) |
| "Tranexamic acid treatment was associated with a significant decrease in serum IL-1β at six and 24 hours and IL-10 at 24 hours from start of shock compared to vehicle control." | 5.48 | Tranexamic acid decreases rodent hemorrhagic shock-induced inflammation with mixed end-organ effects. ( Bradley, MJ; Davis, TA; Foster, AD; Rothberg, PA; Walker, PF, 2018) |
| "Tranexamic acid (TXA) has been shown clinically to reduce mortality in hemorrhaging and head-injured trauma patients and has the potential to mitigate secondary brain injury with its reported antifibrinolytic and antiinflammatory properties." | 5.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| "The aim of this study was to evaluate the effects of a high initial-dose (60 mg/kg) intravenous tranexamic acid (IV-TXA) on fibrinolysis and inflammation after total knee arthroplasty (TKA)." | 5.34 | The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial. ( Huang, Q; Huang, W; Lei, YT; Pei, FX; Xie, JW, 2020) |
| "To explore the effect of intravenous tranexamic acid (IV-TXA) on inflammation and immune response following primary total knee arthroplasty (TKA)." | 5.34 | Tranexamic acid attenuates inflammatory effect and modulates immune response in primary total knee arthroplasty: a randomized, placebo-controlled, pilot trial. ( Cao, G; Lei, Y; Pei, F; Xie, J; Xu, H; Zhang, S, 2020) |
| "Experimental allergic encephalomyelitis (EAE) is a prototypic neuroautoimmune disease involving sensitization to central nervous system myelin basic protein (MBP)." | 4.77 | Role of the clotting system in the pathogenesis of neuroimmunologic disease. ( Koh, CS; Kwaan, HC; Paterson, PY, 1987) |
| " The purpose of this study was to compare the effects of intra-articular (IA) administration of tranexamic acid (TXA), an anti-fibrinolytic commonly used in TKA, and ALM chondroprotective solution on postoperative inflammation and joint tissue healing in a rat model of knee implant surgery." | 4.02 | Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty. ( Biros, E; Dlaska, C; Dobson, GP; Hazratwala, K; Letson, HL; McEwen, P; Morris, JL; Wilkinson, M, 2021) |
| "Intravenous tranexamic acid (TXA) is an effective adjunct after hemorrhagic shock (HS) because of its antifibrinolytic properties." | 3.83 | Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock. ( Ban, K; Kozar, RA; LeBlanc, A; Peng, Z, 2016) |
| " Second, treatment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of fibrinogen from the circulation of AD mice with ancrod treatment attenuated measures of neuroinflammation and vascular pathology." | 3.74 | Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. ( Melchor, JP; Paul, J; Strickland, S, 2007) |
| "Tranexamic acid (TXA) has been shown to be effective in reducing blood loss for patients undergoing THA, but few studies focus on its alleviation of postoperative local pain symptoms." | 3.30 | Topical use of tranexamic acid can reduce opioid consumption compared with intravenous use for patients undergoing primary total hip arthroplasty: a prospective randomized controlled trial. ( Jiang, Z; Shen, L; Wang, Q; Xu, W, 2023) |
| "The hemostatic effect of tranexamic acid (TXA) combined with carbazochrome sodium sulfonate (CSS) in total hip arthroplasty (THA) has not been determined." | 3.11 | Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial. ( Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022) |
| "Tranexamic acid (TXA) reduces surgical blood loss and alleviates inflammatory response in total hip arthroplasty." | 2.90 | Effect of Multiple Doses of Oral Tranexamic Acid on Haemostasis and Inflammatory Reaction in Total Hip Arthroplasty: A Randomized Controlled Trial. ( He, C; Li, Q; Luo, ZY; Pei, FX; Wang, D; Yang, Y; Zeng, WN; Zhou, ZK, 2019) |
| "The optimal dosage and timing of tranexamic acid (TXA) in total knee arthroplasty (TKA) are undetermined." | 2.82 | Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial. ( Ma, J; Pei, F; Xie, J; Yao, H; Yue, C, 2016) |
| " Considering the dosage and duration of treatment, an optimal protocol may be needed to induce the efficacy of this treatment to achieve the PIH-preventing effect of oral TA." | 2.76 | A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser. ( Araki, J; Doi, K; Eto, H; Higashino, T; Hirai, R; Kato, H; Kuno, S; Yoshimura, K, 2011) |
| "Tranexamic acid is a promising future treatment for psoriasis." | 1.91 | Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies. ( Chan, CI; Chen, SJ; Hseu, JH; Hseu, YC; Vadivalagan, C; Wu, PY; Yang, HL; Yen, HR, 2023) |
| "Tranexamic acid treatment was associated with a significant decrease in serum IL-1β at six and 24 hours and IL-10 at 24 hours from start of shock compared to vehicle control." | 1.48 | Tranexamic acid decreases rodent hemorrhagic shock-induced inflammation with mixed end-organ effects. ( Bradley, MJ; Davis, TA; Foster, AD; Rothberg, PA; Walker, PF, 2018) |
| "Tranexamic acid (TXA) has been shown clinically to reduce mortality in hemorrhaging and head-injured trauma patients and has the potential to mitigate secondary brain injury with its reported antifibrinolytic and antiinflammatory properties." | 1.46 | Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage. ( Boudreau, RM; Caldwell, CC; Friend, LA; Goetzman, H; Goodman, MD; Johnson, M; Makley, AT; Pritts, TA; Veile, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.89) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 3 (7.89) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 14 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, Y | 1 |
| Releken, Y | 1 |
| Yang, D | 1 |
| Yue, Y | 1 |
| Liu, Z | 1 |
| Kang, P | 1 |
| Morris, JL | 2 |
| Letson, HL | 2 |
| McEwen, P | 2 |
| Biros, E | 1 |
| Dlaska, C | 1 |
| Hazratwala, K | 2 |
| Wilkinson, M | 2 |
| Dobson, GP | 2 |
| Wallen, TE | 1 |
| Singer, KE | 1 |
| Baucom, MR | 1 |
| England, LG | 1 |
| Schuster, RM | 1 |
| Pritts, TA | 2 |
| Goodman, MD | 2 |
| Jiang, W | 1 |
| Wang, X | 1 |
| Xu, H | 2 |
| Liu, M | 1 |
| Xie, J | 5 |
| Huang, Q | 4 |
| Zhou, R | 1 |
| Zhou, Z | 1 |
| Pei, F | 5 |
| Shen, L | 1 |
| Jiang, Z | 1 |
| Wang, Q | 1 |
| Xu, W | 1 |
| Hseu, JH | 1 |
| Chan, CI | 1 |
| Vadivalagan, C | 1 |
| Chen, SJ | 1 |
| Yen, HR | 1 |
| Hseu, YC | 1 |
| Yang, HL | 1 |
| Wu, PY | 1 |
| Lei, YT | 1 |
| Xie, JW | 1 |
| Huang, W | 2 |
| Pei, FX | 3 |
| Zhang, S | 1 |
| Cao, G | 1 |
| Lei, Y | 2 |
| Briggs, GD | 1 |
| Balogh, ZJ | 1 |
| An, YZ | 1 |
| Xu, MD | 1 |
| An, YC | 1 |
| Liu, H | 1 |
| Zheng, M | 1 |
| Jiang, DM | 1 |
| da Silva Souza, ID | 1 |
| Lampe, L | 1 |
| Winn, D | 1 |
| Fenger-Eriksen, C | 1 |
| Rasmussen, M | 1 |
| Juul, N | 1 |
| Krog, J | 1 |
| Hvas, AM | 1 |
| Keragala, CB | 1 |
| Medcalf, RL | 1 |
| Boudreau, RM | 1 |
| Johnson, M | 1 |
| Veile, R | 1 |
| Friend, LA | 1 |
| Goetzman, H | 1 |
| Caldwell, CC | 1 |
| Makley, AT | 1 |
| Hu, Q | 1 |
| Ma, J | 2 |
| Liu, JL | 1 |
| Zeng, WN | 3 |
| Wang, FY | 1 |
| Chen, C | 2 |
| Gong, XY | 1 |
| Yang, H | 1 |
| Tan, ZJ | 1 |
| Jia, XL | 1 |
| Yang, L | 1 |
| Grant, AL | 1 |
| Wang, D | 2 |
| Luo, ZY | 2 |
| Yu, ZP | 1 |
| Liu, LX | 1 |
| Meng, WK | 1 |
| Yu, QP | 1 |
| Zhou, ZK | 2 |
| Walker, PF | 1 |
| Foster, AD | 1 |
| Rothberg, PA | 1 |
| Davis, TA | 1 |
| Bradley, MJ | 1 |
| Yang, Y | 2 |
| He, C | 1 |
| Li, Q | 1 |
| Zubair, R | 1 |
| Lyons, AB | 1 |
| Vellaichamy, G | 1 |
| Peacock, A | 1 |
| Hamzavi, I | 1 |
| Tang, Y | 1 |
| Wen, Y | 1 |
| Li, W | 1 |
| Li, H | 1 |
| Liu, Y | 1 |
| Chen, TT | 1 |
| Wang, G | 1 |
| Jiang, SL | 1 |
| Li, LB | 1 |
| Gao, CQ | 1 |
| Lerchenberger, M | 1 |
| Uhl, B | 1 |
| Stark, K | 1 |
| Zuchtriegel, G | 1 |
| Eckart, A | 1 |
| Miller, M | 1 |
| Puhr-Westerheide, D | 1 |
| Praetner, M | 1 |
| Rehberg, M | 1 |
| Khandoga, AG | 1 |
| Lauber, K | 1 |
| Massberg, S | 1 |
| Krombach, F | 1 |
| Reichel, CA | 1 |
| Bock, A | 1 |
| Tucker, N | 1 |
| Kelher, MR | 1 |
| Khan, SY | 1 |
| Gonzalez, E | 1 |
| Wohlauer, M | 1 |
| Hansen, K | 1 |
| Dzieciatkowska, M | 1 |
| Sauaia, A | 1 |
| Banerjee, A | 1 |
| Moore, EE | 1 |
| Silliman, CC | 1 |
| Peng, Z | 1 |
| Ban, K | 1 |
| LeBlanc, A | 1 |
| Kozar, RA | 1 |
| Yao, H | 1 |
| Yue, C | 1 |
| Kato, H | 1 |
| Araki, J | 1 |
| Eto, H | 1 |
| Doi, K | 1 |
| Hirai, R | 1 |
| Kuno, S | 1 |
| Higashino, T | 1 |
| Yoshimura, K | 1 |
| McDaniel, DH | 1 |
| Later, AF | 1 |
| Sitniakowsky, LS | 1 |
| van Hilten, JA | 1 |
| van de Watering, L | 1 |
| Brand, A | 1 |
| Smit, NP | 1 |
| Klautz, RJ | 1 |
| Swaisgood, CM | 1 |
| Aronica, MA | 1 |
| Swaidani, S | 1 |
| Plow, EF | 1 |
| Paul, J | 1 |
| Strickland, S | 1 |
| Melchor, JP | 1 |
| Brosnan, CF | 1 |
| Cammer, W | 1 |
| Norton, WT | 1 |
| Bloom, BR | 1 |
| Velky, TS | 1 |
| Greenburg, AG | 1 |
| Yang, JC | 1 |
| Forbes, S | 1 |
| Blinder, D | 1 |
| Martinowitz, U | 1 |
| Ardekian, L | 1 |
| Peleg, M | 1 |
| Taicher, S | 1 |
| Cvachovec, K | 1 |
| Horácek, M | 1 |
| Vislocký, I | 1 |
| Paterson, PY | 1 |
| Koh, CS | 1 |
| Kwaan, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial[NCT05099276] | Phase 4 | 46 participants (Actual) | Interventional | 2021-12-07 | Active, not recruiting | ||
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events[NCT05313620] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application, a Comparison With Intravenous Tranexamic Acid Only in Total Hip Arthroplasty[NCT03623789] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-08-15 | Recruiting | ||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
3 reviews available for tranexamic acid and Inflammation
| Article | Year |
|---|---|
Plasminogen: an enigmatic zymogen.
Topics: Animals; Antifibrinolytic Agents; Brain; Conjunctivitis; Enzyme Activation; Fibrin; Fibrinolysin; Fi | 2021 |
What's New in Pigmentary Disorders.
Topics: alpha-MSH; Antifibrinolytic Agents; Bimatoprost; Dermatologic Agents; Humans; Hydroquinones; Inflamm | 2019 |
Role of the clotting system in the pathogenesis of neuroimmunologic disease.
Topics: Animals; Blood Coagulation; Blood-Brain Barrier; Cerebrovascular Circulation; Encephalomyelitis, Aut | 1987 |
18 trials available for tranexamic acid and Inflammation
| Article | Year |
|---|---|
Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Topics: Adrenochrome; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Hemosta | 2022 |
Tourniquets can further reduce perioperative blood loss in patients on dexamethasone and tranexamic acid during cemented total knee arthritis: a single-center, double-blind, randomized controlled trial.
Topics: Albumins; Antifibrinolytic Agents; Arthritis; Blood Loss, Surgical; Dexamethasone; Humans; Inflammat | 2023 |
Topical use of tranexamic acid can reduce opioid consumption compared with intravenous use for patients undergoing primary total hip arthroplasty: a prospective randomized controlled trial.
Topics: Administration, Intravenous; Administration, Topical; Analgesics, Opioid; Antifibrinolytic Agents; A | 2023 |
The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, | 2020 |
Tranexamic acid attenuates inflammatory effect and modulates immune response in primary total knee arthroplasty: a randomized, placebo-controlled, pilot trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, | 2020 |
Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surg | 2020 |
Combined Application of Dexamethasone and Tranexamic Acid to Reduce the Postoperative Inflammatory Response and Improve Functional Outcomes in Total Hip Arthroplasty.
Topics: Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; C-Reactive | 2020 |
Effect of tranexamic acid on markers of inflammation in children undergoing craniofacial surgery.
Topics: Antifibrinolytic Agents; Biomarkers; Blood Loss, Surgical; Child; Double-Blind Method; Humans; Infla | 2021 |
Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomised clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Biomarkers; | 2017 |
Effects of low-dose epinephrine on perioperative hemostasis and inflammatory reaction in major surgical operations: a randomized clinical trial.
Topics: Adrenergic Agonists; Adult; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, R | 2018 |
The antifibrinolytic and anti-inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antifibrinolytic Agents; Arthroplasty, Replace | 2018 |
Effect of Multiple Doses of Oral Tranexamic Acid on Haemostasis and Inflammatory Reaction in Total Hip Arthroplasty: A Randomized Controlled Trial.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Lo | 2019 |
The efficacy and safety of multiple doses of oral tranexamic acid on blood loss, inflammatory and fibrinolysis response following total knee arthroplasty: A randomized controlled trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Double-Blind M | 2019 |
Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery.
Topics: Anti-Inflammatory Agents; Antifibrinolytic Agents; China; Comorbidity; Drug Therapy, Combination; Gl | 2013 |
Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial.
Topics: Administration, Intravenous; Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomark | 2016 |
A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Female; Humans; Hyperpigmentation; Infla | 2011 |
Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery.
Topics: Aged; Antifibrinolytic Agents; Aprotinin; Cardiac Surgical Procedures; Cardiovascular Diseases; Case | 2013 |
A retrospective survey of fibrinolysis as an indicator of poor outcome after cardiopulmonary bypass and a possible early sign of systemic inflammation syndrome.
Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiopulmonary Bypass; Female; Fibrinolysis; H | 2000 |
17 other studies available for tranexamic acid and Inflammation
| Article | Year |
|---|---|
Comparison of intra-articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty.
Topics: Adenosine; Administration, Intravenous; Animals; Antifibrinolytic Agents; Arthroplasty, Replacement, | 2021 |
Effects of antifibrinolytics on systemic and cerebral inflammation after traumatic brain injury.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Brain Injuries, Traumatic; Chemokine CCL2; Chem | 2022 |
Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies.
Topics: Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammasomes; Inflammation; Interle | 2023 |
Tranexamic acid and inflammation in trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Inflammation; Tranexamic Acid; Wounds and Injuries | 2020 |
New topical tranexamic acid derivative for the improvement of hyperpigmentation and inflammation in the sun-damaged skin.
Topics: Dermatologic Agents; Female; Humans; Hyperpigmentation; Inflammation; Quality of Life; Tranexamic Ac | 2021 |
Impact of tranexamic acid on coagulation and inflammation in murine models of traumatic brain injury and hemorrhage.
Topics: Animals; Anti-Inflammatory Agents; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; | 2017 |
Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Biomarkers; Blood Coagulation; Blood | 2018 |
Tranexamic acid decreases rodent hemorrhagic shock-induced inflammation with mixed end-organ effects.
Topics: Animals; Antifibrinolytic Agents; Inflammation; Lung; Lymph Nodes; Male; Myocardium; Rats, Sprague-D | 2018 |
Matrix metalloproteinases modulate ameboid-like migration of neutrophils through inflamed interstitial tissue.
Topics: Aminocaproates; Animals; Aprotinin; Chemotaxis, Leukocyte; Immune System Diseases; Inflammation; Leu | 2013 |
α-Enolase Causes Proinflammatory Activation of Pulmonary Microvascular Endothelial Cells and Primes Neutrophils Through Plasmin Activation of Protease-Activated Receptor 2.
Topics: Acute Lung Injury; Cell Membrane; Endothelial Cells; Flow Cytometry; Humans; Inflammation; Intercell | 2015 |
Intraluminal tranexamic acid inhibits intestinal sheddases and mitigates gut and lung injury and inflammation in a rodent model of hemorrhagic shock.
Topics: ADAM17 Protein; Animals; Enzyme-Linked Immunosorbent Assay; Inflammation; Intestinal Mucosa; Intesti | 2016 |
Use of oral therapy for the prevention of postinflammatory hyperpigmentation.
Topics: Administration, Oral; Antifibrinolytic Agents; Humans; Hyperpigmentation; Inflammation; Japan; Laser | 2011 |
Plasminogen is an important regulator in the pathogenesis of a murine model of asthma.
Topics: Animals; Antifibrinolytic Agents; Asthma; Bronchoalveolar Lavage Fluid; Collagen; Disease Models, An | 2007 |
Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Disease Models, Animal; Disease Progression; Fibrin | 2007 |
Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis.
Topics: Aminocaproic Acid; Animals; Aprotinin; Benzoates; Encephalomyelitis, Autoimmune, Experimental; Guani | 1980 |
Modulators of plasma fibronectin response during sepsis.
Topics: Aminocaproic Acid; Animals; Blood Coagulation; Cecum; Endotoxins; Escherichia coli; Fibronectins; In | 1984 |
[Oral surgical procedures during anticoagulant therapy].
Topics: Adult; Aged; Anticoagulants; Coumarins; Dental Cements; Female; Gelatin Sponge, Absorbable; Hemostas | 1996 |